Acute respiratory distress syndrome (ARDS) is a syndrome of acute respiratory failure
caused by noncardiogenic pulmonary edema. Despite five decades of basic and clinical …

The acute respiratory distress syndrome (ARDS) is a common cause of respiratory failure in
critically ill patients and is defined by the acute onset of noncardiogenic pulmonary oedema …

Rationale: Acute respiratory distress syndrome (ARDS) remains a major cause of respiratory
failure in critically ill patients. Mesenchymal stromal cells (MSCs) are a promising candidate …

Mesenchymal stromal cells (MSC) have been reported to improve bacterial clearance in
preclinical models of Acute Respiratory Distress Syndrome (ARDS) and sepsis. The …

Background No effective pharmacotherapy for acute respiratory distress syndrome (ARDS)
exists, and mortality remains high. Preclinical studies support the efficacy of mesenchymal …

The acute respiratory distress syndrome (ARDS) is an important cause of acute respiratory
failure that is often associated with multiple organ failure. Several clinical disorders can …

Background We previously reported that microvesicles (MVs) released by human
mesenchymal stem cells (MSC) were as effective as the cells themselves in both …

Mesenchymal stem cells (MSC) have generated a great amount of enthusiasm over the past
decade as a novel therapeutic paradigm for a variety of diseases. Currently, MSC based …

Introduction: Mesenchymal stem/stromal cells (MSCs) have been shown to improve lung
function and survival in chronic inflammatory lung diseases, including asthma, chronic …

On the basis of several preclinical studies, cell-based therapy has emerged as a potential
new therapeutic for acute respiratory distress syndrome (ARDS). Of the various cell-based …